MedElevator
Войти в исследования Frontiers in immunology · 2022
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Parisi Sarah, Ruggeri Loredana, Dan Elisa, Rizzi Simonetta, Sinigaglia Barbara, Ocadlikova Darina, Bontadini Andrea, Giudice Valeria, Urbani Elena, Ciardelli Sara, Sartor Chiara, Cristiano Gianluca, Nanni Jacopo, Zannoni Letizia, Chirumbolo Gabriella, Arpinati Mario, Lewis Russell E, Bonifazi Francesca, Marconi Giovanni, Martinelli Giovanni, Papayannidis Cristina, Paolini Stefania, Velardi Andrea, Cavo Michele, Lemoli Roberto M, Curti Antonio
Аннотация
Recently, many reports were published supporting the clinical use of adoptively transferred natural killer (NK) cells as a therapeutic tool against cancer, including acute myeloid leukemia (AML). Our group demonstrated promising clinical response using adoptive immunotherapy with donor-derived alloreactive KIR-ligand-mismatched NK cells in AML patients. Moreover, the antileukemic effect was correlated with the dose of infused alloreactive NK cells ("functional NK cell dose"). Herein, we update the results of our previous study on a cohort of adult AML patients (median age at enrollment 64) in first morphological complete remission (CR), not eligible for allogeneic stem cell transplantation. After an extended median follow-up of 55.5 months, 8/16 evaluable patients (50%) are still off-therapy and alive disease-free. Overall survival (OS) and disease-free survival (DFS) are related with the dose of infused alloreactive NK cells (≥2 × 105/kg).